Callahan Advisors LLC Has $18.31 Million Stock Position in Stryker Co. (NYSE:SYK)

Callahan Advisors LLC lifted its position in Stryker Co. (NYSE:SYK) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,864 shares of the medical technology company’s stock after buying an additional 167 shares during the quarter. Stryker comprises approximately 1.7% of Callahan Advisors LLC’s holdings, making the stock its 15th largest position. Callahan Advisors LLC’s holdings in Stryker were worth $18,313,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Davidson Investment Advisors lifted its stake in shares of Stryker by 2.2% in the fourth quarter. Davidson Investment Advisors now owns 1,390 shares of the medical technology company’s stock worth $500,000 after buying an additional 30 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in shares of Stryker by 3.0% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 10,453 shares of the medical technology company’s stock worth $3,764,000 after buying an additional 302 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Stryker in the fourth quarter worth $1,906,000. Atria Wealth Solutions Inc. lifted its stake in shares of Stryker by 2.4% in the fourth quarter. Atria Wealth Solutions Inc. now owns 16,607 shares of the medical technology company’s stock worth $5,987,000 after buying an additional 389 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in shares of Stryker by 2.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,789 shares of the medical technology company’s stock worth $644,000 after buying an additional 42 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Royal Bank of Canada boosted their target price on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Evercore ISI boosted their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Barclays boosted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Stock Down 0.9 %

SYK opened at $385.05 on Tuesday. The firm’s 50-day simple moving average is $377.39 and its 200-day simple moving average is $367.56. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $146.79 billion, a price-to-earnings ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business posted $3.46 EPS. Equities research analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.